Olmesartan/Amlodipine/Hctz Krka (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipine/Hctz Krka, is an angiotensin II receptor blocker (ARB) presented as a combination tablet for oral use. It treats hypertension, often in patients who require multiple mechanisms to control blood pressure. GNH USA supplies Olmesartan/Amlodipine/Hctz Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan/Amlodipine/Hctz Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine/Hctz combines three agents that act on the renin‑angiotensin system and vascular smooth‑muscle tone to lower blood pressure.

- Hypertension: provides combined blockade of angiotensin II receptors, calcium‑channel mediated vasodilation, and diuresis to achieve target blood‑pressure control. - Resistant hypertension: adds a thiazide‑type diuretic to an ARB/CCB regimen when monotherapy or dual therapy is insufficient. - Hypertension with edema: amlodipine‑induced peripheral edema is mitigated by the diuretic component, improving tolerability.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Peripheral edema - Flushing - Fatigue - Increased urination

Serious or Rare Side Effects: - Severe hypotension - Electrolyte disturbances (e.g., low potassium, sodium) - Acute kidney injury - Angio‑edema - Liver enzyme elevation - Blood cell abnormalities (e.g., leukopenia, thrombocytopenia)

Before initiating therapy, clinicians should assess individual risk factors and monitor relevant parameters.

- Renal function: evaluate baseline creatinine and eGFR, adjust if impaired. - Electrolytes: check potassium and sodium levels, especially with diuretic use. - Pregnancy: contraindicated in the second and third trimesters; avoid unless clearly needed. - Concomitant drugs: review for potential additive blood‑pressure lowering effects. - Elderly patients: start at lower dose and monitor for orthostatic symptoms. - Store at ambient temperature: keep tablets in original container, protect from moisture and direct sunlight.

Olmesartan/Amlodipine/Hctz may interact with several drug classes; careful review is essential.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitor, another ARB): risk of hyperkalaemia and renal impairment. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine levels, raising hypotension risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Lithium: can increase lithium concentrations, risking toxicity. - Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment. - Alcohol: additive vasodilatory effect may increase dizziness. - Digoxin: monitor levels as electrolyte shifts can affect cardiac conduction.